Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHXTNW)

Drug Name
LY-2228820 Drug Info
Synonyms
Ralimetinib; 862505-00-8; LY-2228820 free base; UNII-73I34XW4HD; 73I34XW4HD; 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-Imidazo[4,5-b]pyridin-2-amine; C24H29FN6; Ralimetinib [USAN:INN]; LY2228820 free base; Ralimetinib (USAN/INN); GTPL7959; SCHEMBL3989306; SCHEMBL13826263; CHEMBL2364626; DTXSID00235456; MolPort-009-679-493; XPPBBJCBDOEXDN-UHFFFAOYSA-N; BCPP000180; BCP02033; ZINC34630490; ABP000309; 2526AH; ABP000548; AKOS027282678; SB16635; BCP9000871; DB11787; NCGC00346537-05; LY-2180895; LY-2211877; LY-2228820 mesylate; LY-2231377; LY-2322600; LY-479754; LY-22288202MsOH; P38 MAP kinase inhibitors (inflammation, cancer), Lilly
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Cross-matching ID
PubChem CID
11539025
CAS Number
CAS 862505-00-8
TTD Drug ID
DMHXTNW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Stress-activated protein kinase (p38)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PF-07265803 DM3E6Q4 Dilated cardiomyopathy BC43.0 Phase 3 [2]
ARRY-797 DMJ48AB Dilated cardiomyopathy BC43.0 Phase 2 [3]
BMS-582949 DMGYXFP Atherosclerosis BD40 Phase 2 [4]
AZD7624 DMEW3K9 Chronic obstructive pulmonary disease CA22 Phase 2 [5]
GSK2269557 DMIN0SV Asthma CA23 Phase 2 [6]
TAK-715 DMZKPI8 Rheumatoid arthritis FA20 Phase 2 [7]
MW150 DMBRVXB Alzheimer disease 8A20 Phase 2 [8]
PUR1800 DM6H10N Chronic obstructive pulmonary disease CA22 Phase 1 [9]
ARRY-614 DMXD93K Arthritis FA20 Discontinued in Phase 1 [10]
TA-5493 DMFES2K Inflammation 1A00-CA43.1 Discontinued in Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Stress-activated protein kinase (p38) TTWELHI NOUNIPROTAC Inhibitor [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959).
2 Clinical pipeline report, company report or official report of Pfizer
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33.
5 Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
6 Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557. Expert Opin Ther Pat. 2012 Aug;22(8):965-70.
7 Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/ . Chem Biol. 2011 Apr 22;18(4):485-94.
8 p38alpha MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10245-E10254.
9 Clinical pipeline report, company report or official report of Pulmatrix Lexington, MA
10 Cmpany report (Arraybiopharma)
11 US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.